E. Ohman J:or Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

E. Ohman J:or Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-85,000	Closed	-$3.94M	–	435
2022 Q4	$3.94M	Buy	85,000 +13,000	+18%	+$511K	0.17%	88
2022 Q3	$2.98M	Buy	72,000 +20,000	+38%	+$1.03M	0.14%	99
2022 Q2	$3.1M	Buy	+52,000	New	+$3.2M	0.13%	98

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

E. Ohman J:or Asset Management's RARE Position: Q1 2023 in Review

E. Ohman J:or Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2023, closing a stake of 85,000 shares — an estimated $3.94M sold.

E. Ohman J:or Asset Management first reported a position in RARE in Q2 2022 and held it in 3 quarters. The position peaked at $3.94M in Q4 2022. 228 funds tracked by Wall St. Rank hold RARE as of Q1 2023.

E. Ohman J:or Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2023 after selling out during the quarter.
E. Ohman J:or Asset Management sold 85,000 Ultragenyx Pharmaceutical shares in Q1 2023, an estimated $3.94M.
E. Ohman J:or Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2022 and held it in 3 quarters.
E. Ohman J:or Asset Management's Ultragenyx Pharmaceutical position peaked at $3.94M in Q4 2022.
228 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2023.

Based on E. Ohman J:or Asset Management's 13F filing for Q1 2023, filed 5 Apr 2024.